Kornimate/medical-research-clean huggingface dataset:
virtual focused act groups in primary care

Conditions: Depression; Anxiety; Quality of Life; Acceptance Processes

Summary: acceptance and commitment therapy (act) is a transdiagnostic intervention whose aim is to reduce experiential avoidance and promote psychological flexibility, which involves engaging in values-based behaviour while accepting painful internal experiences with openness and awareness. a growing body of research supports the efficacy of brief act for a variety of issues, including depression, anxiety, chronic pain, and stress. given that act is a transdiagnostic intervention that targets the core processes related to human suffering, this treatment may be particularly useful for implementation in primary care with diverse groups of individuals and presentations. the objective of this study is to develop and pilot test a brief, virtual, group-based act intervention for depression and anxiety delivered in primary care settings to determine if a future randomized controlled trial of this group treatment is both warranted and feasible. the investigators will examine (1) the feasibility and acceptability of the study procedures, (2) clinician adherence to the treatment protocol, and (3) a preliminary analysis of the treatment effectiveness. a total of 3 groups (n = 30-45) will be conducted via three primary care clinics in winnipeg, manitoba, canada. the group treatment will be delivered over four 90-minute sessions. participants will complete assessment measures at pretreatment, post-treatment, and at two follow-up time points (1-month post-treatment and 3-6-months post-treatment). all assessments and treatment sessions will be conducted virtually via videoconferencing platform.


Eligibility criteria:
inclusion criteria: * self-reported symptoms of depression and/or anxiety * fluent in english * access to reliable internet and a device with a webcam as well as a private/quite space from which to attend sessions * no change in psychotropic medication for at least 6 weeks prior to the intervention * willingness to maintain a stable medication type and dose for psychotropic medications during the intervention phase and for one month post-intervention exclusion criteria: * engagement in another psychological treatment during the intervention phase or one month post-intervention * current psychosis * bipolar disorder * current substance use disorder * cognitive/intellectual impairment * current active suicidal ideation
the effects of mindfulness training on eating behaviors and food intake

Conditions: Obesity; Feeding Behavior

Summary: the investigators propose to study the effect of mindfulness training on the eating behaviors and dietary intake of overweight or obese persons. mindfulness skills training involves bringing non-judgmental attention to thoughts, emotions and bodily sensations - including hunger and satiety cues. it is hypothesized that as subjects advance through the 8-week class series, developing their capacity for mindfulness and in effect learn to pay attention to the sensations, assumptions, cognitions, and beliefs that underlie their eating behaviors, that their eating behaviors will improve. specifically, the investigators hypothesize that 1) there will be significant improvements in the areas of uncontrolled and emotional eating, 2) there will be significant decreases in total caloric intake and significant increases in fruits and vegetables, and 3) there will be a positive significant relationship between the frequency/consistency of mindfulness practice and improvements from baseline to follow-up measures.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) \> 26 exclusion criteria: * psychotic disorders * poorly controlled bipolar disorder * borderline or antisocial personality disorder * a diagnosed eating disorder
analysis of cytokines in response to treatment of diabetic macular edema with 0.3mg lucentis

Conditions: Diabetic Macular Edema

Summary: the protocol will measure a number of cytokines in addition to vascular endothelial growth factor in response to 0.3mg lucentis.

lucentis injections are the current standard of care for diabetic macular edema. the only deviation from the standard of care in the current protocol is an aqueous tap before the first lucentis injection and the fourth lucentis injection for diabetic macular edema.

Eligibility criteria:
inclusion criteria: * diagnosis of diabetes mellitus * best corrected visual acuity 20/32 - 20/320 * diabetic macular edema involving the center of the macula * optical coherence tomography central subfield thickness of at least 250 microns exclusion criteria: * history of anti-vascular endothelial growth factor treatment in the past 12 months * any diabetic macular edema treatment in the past 4 months * heart attack, stroke, transient ischemic attack or acute congestive heart failure within 4 months
evaluation of the observance and the tolerance of a motor training program

Conditions: Hemiplegia; Stroke

Summary: transcortical direct current stimulation (tdcs) is an emerging technique in the rehabilitation of hemiplegic patients after stroke. this study aims to assess the observance and the tolerance of repeated tdcs stimulation over the primary motor cortex of the lower limb coupled to a motor training program, among hemiplegic patients at the sub-acute stage. this is a prospective, randomized, double-blind, study with two parallel groups of 15 subjects each. the study will analyze first, the patient's observance considered good if 75% of the patients completed the entire protocol duration and the tolerance through a questionnaire. the secondary end point will try to estimate, if possible, the effect size of the walking performance measured with the six-minute walk test and aerobic performance measured with vo2peak of this training program compared to the same program combine with placebo stimulations. these evaluations are performed before, during and after the rehabilitation program.

during the initial 20 min of each session, the patient received a 2 ma anodal tdcs over the lower limb ipsilesional motor area. the anodal electrode was positioned on the hotspot previously identified with tms. the cathode was placed above the contralesional orbit. the pseudo stimulation reproduces during the first and the last 30 seconds of the stimulation, tingling feelings due to current flow experienced during tdcs. in this way there is no possibility for the patient to recognize the difference between the real and the placebo stimulation.

Eligibility criteria:
inclusion criteria: * having had a first ischemic stroke within 6 months, or have already had a stroke in the same lesion zone. * no recurrence. * responsible of a right or left hemiplegia. * able to walk alone with or without technical assistance. * over a distance of at least 10 meters. * performance on the six-minute walk test less than 400 meters. * without neurological history other than stroke. exclusion criteria: * patients who did not have brain mri after their stroke * patients with complete lesion of the primary motor cortex (as identified on mri). * patients with an addiction to alcohol or drugs. * patients with psychiatric disease, cognitive impairment disease, uncontrolled epilepsy, neoplastic disease, severe renal or pulmonary failure. * patients with cerebellar syndrome associated. * patients with clinical involvement of the brainstem (cranial nerve deficit). * patients who refused to sign the written consent. * patients who have an ongoing pregnancy. * patients under justice protection. * patients with contraindication to practice aerobic training after stress test.

Keywords: stroke hemiplegia transcranial direct current stimulation (tdcs) rehabilitation lower extremity gait training
study of the effect of flutter® vrp1 (pep and oscillating high frequency).

Conditions: Bronchiectasis

Summary: the research sought to assess the effects of flutter ® vrp1 in patients with bronchiectasis.

bronchiectasis is an airway disease with many etiologies characterized pathologically by the abnormal permanent dilatation of bronchi, caused mainly by the perpetuation of inflammatory processes induced by frequent episodes of bacterial infections, with consequent change in the ciliated epithelial lining and compromising the effectiveness of mucociliary clearance that can favor the hypersecretive state found in these patients. in addition to drug therapy or surgical treatment, patients with bronchiectasis also have physiotherapy, which is an important part in treatment. the patients present impaired mucus transport, and can enjoy the benefits provided by respiratory therapy, which features intended to increase the removal of airway secretions and thus reduce the obstruction to improve ventilation and oxygenation. one of the instruments commonly used in respiratory therapy is the flutter ® vrp1 (varioraw sa, switzerland), which is a simple equipment, small, similar to a pipe that combines two techniques: positive expiratory pressure (pep) and high-frequency oscillations. some previous studies have shown beneficial effects after use of this device in patients with bronchiectasis. however, it is unclear whether the mechanism of action is related to the combination of pep and the techniques of high frequency oscillation, or just one of those components.

Eligibility criteria:
inclusion criteria: * non cystic fibrosis bronchiectasis * amount of secretion sufficient for analysis * capable of fulfilling the experimental protocol exclusion criteria: * acute pulmonary disease * presence of any respiratory infection in the last four weeks

Keywords: bronchiectasis pulmonary function respiratory muscle strength respiratory secretions
effect of mulligan medial/lateral glide w/wo compression/decompression technique on pain rom and function ko

Conditions: Knee Osteoarthritis

Summary: the effect of mulligan medial/lateral glide techniques with and without compression-decompression on pain, range of motion and function in patients with knee osteoarthritis. this study aims to investigate these effects to develop more effective, non-invasive treatment protocols for improving pain, range of motion and overall function in knee oa

patients, for the better understanding of response by both treatments (i.e mulligan medial/lateral glide with and without compression/decompression technique). patient which meet inclusion criteria, gave their consent.

Eligibility criteria:
inclusion criteria * unilateral knee oa, males and females between 30 and 60 years of age, * patients with restricted rom, * patients are having more than grade iii strength of knee muscles, * l willingness to take part in the intervention and evaluations exclusion criteria: * patients having unstable knee joint after total knee arthroplasty or medical conditions affecting rehabilitation, * l joint infection of hip and knee, * l soft tissue injuries around knee joints, * including tendinitis and bursitis, * l any fracture including patellar fracture, femur or tibia
a study of the safety of ren001 in patients with primary mitochondrial myopathy

Conditions: Primary Mitochondrial Myopathy

Summary: the purpose of this study is to assess ren001 safety in subjects with primary mitochondrial myopathy


Eligibility criteria:
inclusion criteria: * subjects must give written, signed and dated informed consent * confirmed diagnosis of pmm according to the 2016 rome consensus recommendations * confirmed mitochondrial mutation with evidence of myopathy * able to remain on stable medication throughout the study exclusion criteria: * documented evidence of ongoing rhabdomyolysis * subjects with motor abnormalities other than related to mitochondrial disease * treatment with an investigational drug within 3 months prior to day 1 * hospitalised within 3 months prior to screening for any major medical condition * pregnant or nursing females
a trial for the evaluation of the treatment and outcome of hyperthyroidism with iodized salt and non iodized salt

Conditions: Hyperthyroidism

Summary: to clarify the influence of iodine intake in salt on the incidence and treatment of hyperthyroidism patients, so as to provide theoretical basis for accurate formulation of iodine intake in salt, and provide strategies for effective prevention and control of hyperthyroidism.


Eligibility criteria:
inclusion criteria: 1. sign informed consent before any research procedure is carried out 2. men or women aged 18-65 (equal) at the age of 1. 3. had been diagnosed as graves hyperthyroidism 4. patients with hyperthyroidism who had not been treated with drugs or stopped taking medicine for more than 3 months 5. reduction to the current dose of hyperthyroidism for more than 2 months exclusion criteria: 1. during the period of pregnancy and lactation, those who plan to be pregnant during the study are not granted medical permission. effective contraceptives 2. for the last 1 months or the need for long-term use of amiodarone 3. the history of anaphylaxis (such as systemic anaphylaxis, vasoedema, epidermal exfoliation) etc.) 4. consecutive use of beta receptor blockers for the last 2 weeks 5. over the past six months, systemic use of corticosteroids (oral or intravenous) is continuous more than 7 days 6. there was an obvious liver disease, showing one of the following cases: two consecutive weeks before a. visits. it was confirmed that the measurements of ast or alt were more than 3 times higher than the highest normal value (local data). b. bilirubin synthesis and / or excretion disorders (such as hyperbilirubinemia), and other decompensated liver diseases such as coagulation disorders, hepatic encephalopathy, hypoproteinemia, ascites, and esophagus bleeding from varicose veins. c. acute viral, active, alcoholic, and alcoholic other types of hepatitis 7 visits for 4 weeks before the 1 (or the local data), leukopenia (less than 3 \* 10 9 /l) b/ 0 edition of the first affiliated hospital of the fourth military medical university the first affiliated hospital, the fourth military medical university b/0 edition seventh pages / 13 pages or neutropenia (less than 1.5 \* 10 9 /l) 8 congestive heart failure at grade iii or iv of the new york heart association (nyha) 9 the past 3 months of visit to 1 had a major cardiovascular history, defined as: myocardial infarction plug and coronary angioplasty or bypass surgery, valvular disease or repair, instability angina pectoris, transient ischemic attack, or cerebrovascular accident 10 non well controlled atrial fibrillation 11 diagnosis of malignant tumors over the past 5 years 12 history of medullary thyroid carcinoma 13 organ transplantation or aids history 14 severe exophthalmos has influenced visual acuity 15 over the last 12 months, there is a history of alcohol abuse or drug abuse
effect of noninvasive ventilation on lung function in amyotrophic lateral sclerosis

Conditions: Amyotrophic Lateral Sclerosis; Motor Neuron Disease

Summary: amyotrophic lateral sclerosis (als), or "lou gehrig's disease", is a fatal disorder that causes progressive degeneration and weakening of the muscles of breathing, leading to breathing insufficiency and eventually breathing failure. this breathing insufficiency is commonly treated with a breathing assistance device, known as noninvasive positive pressure ventilation (nippv). while generally well tolerated and accepted, it is not clear whether or to what extent nippv in fact helps breathing function: some data suggest that nippv preserves breathing function over time, whereas other data suggest that it actually causes breathing function to decline more quickly. no studies have shown what the acute effect of nippv is on breathing muscle function in als patients. this study will test the hypothesis that the acute use of nippv, at pressure levels that are in common clinical use, will cause measurable changes in tests of breathing function, compared to baseline and to lower levels of nippv. we expect that the results of this study will help to clarify whether and to what extent nippv assists respiratory muscle function in patients with als.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of amyotrophic lateral sclerosis * clinical indication to start noninvasive ventilation (forced vital capacity \< 50% predicted or signs/symptoms of respiratory insufficiency) * age 18 to 80 years old exclusion criteria: * prior institution of nippv * inability to safely use nippv * indications for tracheostomy assisted ventilation because of inability to clear secretions from the airway * inability or unwillingness to perform pulmonary function testing * presence of advanced dementia.

Keywords: noninvasive ventilation
safety and feasibility evaluation of the aps app

Conditions: Type 1 Diabetes Mellitus

Summary: this clinical trial is a safety and feasibility study to assess the performance of artificial pancreas (ap) system using the zone model predictive control (zone-mpc) and health monitoring system (hms) algorithms embedded into the aps app platform.

the system will be evaluated on up to 10 adult subjects with type 1 diabetes age 18-75 years old at a single clinical site (sansum diabetes research institute), who will complete a 48-hour closed-loop (cl) session in an observed crc environment with medical staff present. during the session subjects will bolus for all meals and snacks and perform a 45-minute walking session while supervised by medical staff. the ap system used consists of an insulin pump, a cgm sensor, and a phone app (the artificial pancreas system \[aps\] phone app).

Eligibility criteria:
inclusion criteria: * age ≥ 18 and ≤ 75 years at the time of screening. * clinical diagnosis of type 1 diabetes for at least one year. * has been using an insulin pump for at least 6 months at the time of screening. * hba1c \< 10.5%. * bolus for all meals and snacks that contain ≥ 5 grams of carbohydrate. * willing to perform at least 7 fingerstick blood glucose tests a day. * if using apidra (insulin glulisine) at home and planning to use the tandem t:ap pump for the closed-loop session, willing to switch to novolog or humalog for the closed-loop session. * willing to refrain from taking acetaminophen products for the duration of the clinical trial. * willing to abide by the study protocol and use study-provided devices, including the omnipod or tandem pump, dexcom cgm, glucometer, ketone meter and aps app on the study phone device. exclusion criteria: * pregnancy * one or more episodes of hypoglycemia requiring an emergency room visit or hospitalization in the past 6 months. * one or more episodes of hyperglycemia requiring an emergency room visit or hospitalization in the past 6 months. * known unstable cardiac disease or untreated cardiac disease, as revealed by history or physical examination. * dermatological conditions that would preclude wearing a cgm sensor or pod/infusion site. * one or more seizures in the past year. * any condition that could interfere with participating in the trial, based on investigator judgment. * participation in another pharmaceutical or device trial at the time of enrollment or during the study.

Keywords: artificial pancreas hyperglycemia hypoglycemia
alpha-1 blockade for alcohol use disorder (aud)

Conditions: Alcohol Use Disorder (AUD)

Summary: the goal of this research is to replicate findings previously conducted in a pilot trial and to understand, mechanistically, the role of stress in the development of aud pharmacotherapies that target noradrenergic blockade.

16 week, between-subject, double-blind, randomized clinical trial (rct) with doxazosin (16 mg, or maximum tolerated dose, mtd) compared to placebo in 184 treatment seeking individuals with aud

Eligibility criteria:
inclusion criteria: * male or female, 18 years of age * meet the dsm-5 criteria for aud * desire to reduce or quit alcohol drinking * breath alcohol (brac) = 0.00 at each visit * in good health as confirmed by medical history, physical examination and lab tests * willing to adhere to the study procedures * understand informed consent and questionnaires in english at an 8th grade level exclusion criteria: * women who are breastfeeding or /positive urine test for pregnancy * crcl\<60ml/min * suicide attempt in the last three months * current diagnosis of other substance disorder other than nicotine as assessed by self-report and urine toxicology screen at baseline * current use of medication that may interact with doxazosin and/or yohimbine * history of allergy to any alpha receptor blockers * clinical institute withdrawal assessment for alcohol revised (ciwa-ar) score ≥ 8 * treatment with disulfiram, naltrexone, acamprosate, topiramate within 1 month prior to screening * treatment with any alpha-blocker * individuals with cardiac heat failure (chf), as assessed by the medical history, the physical exam and the ecg. * baseline hypotension defined as bp reading lower than 90/60 mmhg * use of phosphodiesterase inhibitors (pde5) erectile dysfunction medication

Keywords: alcohol use disorder, stress
novolog observation trial in subjects with type 1 and type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Summary: this trial is conducted in the united states of america (usa). the aim of this trial is to assess control of blood sugar, safety, and patient acceptance of insulin aspart compared to insulin lispro, both in insulin pumps, in standard clinical practice.


Eligibility criteria:
inclusion criteria: * people with type i or type ii diabetes * 18 years or older.

Keywords: diabetes mellitus diabetes